

8. R&D Pipeline

	Stage	Theme	Target	Dosage Form	Characteristics	Next Step
1	Approved	XELSTRYM(ATS)	USA	Patch	Attention Deficit Hyperactivity Disorder(ADHD)	To be launched in FY22
2	Filed	HP-5070	JPN	Transdermal	Primary palmar hyperhidrosis	To be approved in FY23
3	Phase3	HP-5000	USA	Patch	Osteoarthritis of the knee	Under consideration

※Yellow-highlighted parts are changes from the previous announcement made on Oct.12th,2022